Frontal Fibrosing Alopecia: A Comprehensive Review with Recent Updates
View abstract on PubMed
Summary
This summary is machine-generated.Frontal fibrosing alopecia (FFA) is a progressive scarring hair loss condition in postmenopausal women. Research explores its causes, including genetics and immune factors, and evaluates treatments like biological agents.
Area Of Science
- Dermatology
- Trichology
- Pathology
Background
- Frontal fibrosing alopecia (FFA) is a primary lymphocytic scarring alopecia, often considered a variant of lichen planopilaris (LPP).
- Its exact cause is unknown, but genetic, autoimmune, hormonal, and environmental factors are implicated.
- The condition involves hairline recession, shiny atrophic skin, and characteristic histopathological findings.
Purpose Of The Study
- To summarize the current understanding of frontal fibrosing alopecia (FFA).
- To discuss the potential etiopathogenesis, clinical and trichoscopic findings, and diagnostic criteria for FFA.
- To review available and emerging treatment options for FFA.
Main Methods
- Review of existing literature on frontal fibrosing alopecia.
- Analysis of clinical, trichoscopic, and histopathological features.
- Evaluation of proposed diagnostic criteria and treatment outcomes.
Main Results
- FFA presents with frontal and temporoparietal hairline recession and characteristic trichoscopic and histopathological signs.
- Diagnostic criteria by Tolkachjov et al. and the International FFA Cooperative Group are available.
- Current treatments offer limited satisfactory results, prompting investigation into newer agents.
Conclusions
- Frontal fibrosing alopecia is a distinct scarring alopecia with complex potential causes.
- Accurate diagnosis relies on clinical, trichoscopic, and histopathological evaluation.
- Novel treatments, including biological agents like tofacitinib and tildrakizumab, show promise for managing FFA.

